PDUFA, Biosimilar Application Fees To Rise 10.7%; FDA’s Workload Adjuster Needs Work
This article was originally published in The Pink Sheet Daily
Executive Summary
Facility and product user fees will increase by more than 5% for fiscal year 2014; FDA calculated the fees using a revised workload adjuster because the previous method failed to reflect increasing complexity of the drug review process.
You may also be interested in...
PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says
FDA tells industry that proposal on trials also can’t use SPA-like process.
Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says
Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.
FDA User Fees In FY 2014: Burden Per Application Grows As Submission Projections Fall
Agency announces new prescription drug, generic drug and biosimilar rates – with one fee increasing more than 47%.